The Scientific World Journal
Volume 2015 (2015), Article ID 716514, 19 pages
http://dx.doi.org/10.1155/2015/716514
Review Article
Development of PET and SPECT Probes for Glutamate Receptors
Department of Hygienic Chemistry, Graduate School of Biomedical Sciences, Nagasaki University, 1-14 Bunkyo-machi, Nagasaki 852-8521, Japan
Received 28 June 2014; Accepted 29 August 2014
Academic Editor: Masahiro Ono
Copyright © 2015 Takeshi Fuchigami et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Linked References
- S. F. Traynelis, L. P. Wollmuth, C. J. McBain et al., “Glutamate receptor ion channels: Structure, regulation, and function,” Pharmacological Reviews, vol. 62, no. 3, pp. 405–496, 2010. View at Publisher · View at Google Scholar · View at Scopus
- C. M. Niswender and P. J. Conn, “Metabotropic glutamate receptors: physiology, pharmacology, and disease,” Annual Review of Pharmacology and Toxicology, vol. 50, pp. 295–322, 2010. View at Publisher · View at Google Scholar · View at Scopus
- D. Bowie, “Ionotropic glutamate receptors & CNS disorders,” CNS and Neurological Disorders—Drug Targets, vol. 7, no. 2, pp. 129–143, 2008. View at Publisher · View at Google Scholar · View at Scopus
- A. Lau and M. Tymianski, “Glutamate receptors, neurotoxicity and neurodegeneration,” Pflugers Archiv European Journal of Physiology, vol. 460, no. 2, pp. 525–542, 2010. View at Publisher · View at Google Scholar · View at Scopus
- G. Riedel, B. Platt, and J. Micheau, “Glutamate receptor function in learning and memory,” Behavioural Brain Research, vol. 140, no. 1-2, pp. 1–47, 2003. View at Publisher · View at Google Scholar · View at Scopus
- C. G. Lau and R. S. Zukin, “NMDA receptor trafficking in synaptic plasticity and neuropsychiatric disorders,” Nature Reviews Neuroscience, vol. 8, no. 6, pp. 413–426, 2007. View at Publisher · View at Google Scholar · View at Scopus
- J. A. Kemp and R. M. McKernan, “NMDA receptor pathways as drug targets,” Nature Neuroscience, vol. 5, pp. 1039–1042, 2002. View at Publisher · View at Google Scholar · View at Scopus
- L. V. Kalia, S. K. Kalia, and M. W. Salter, “NMDA receptors in clinical neurology: excitatory times ahead,” The Lancet Neurology, vol. 7, no. 8, pp. 742–755, 2008. View at Publisher · View at Google Scholar · View at Scopus
- R. Dingledine, K. Borges, D. Bowie, and S. F. Traynelis, “The glutamate receptor ion channels,” Pharmacological Reviews, vol. 51, no. 1, pp. 7–61, 1999. View at Google Scholar · View at Scopus
- B. Laube, J. Kuhse, and H. Betz, “Evidence for a tetrameric structure of recombinant NMDA receptors,” Journal of Neuroscience, vol. 18, no. 8, pp. 2954–2961, 1998. View at Google Scholar · View at Scopus
- H. Furukawa, S. K. Singh, R. Mancusso, and E. Gouaux, “Subunit arrangement and function in NMDA receptors,” Nature, vol. 438, no. 7065, pp. 185–192, 2005. View at Publisher · View at Google Scholar · View at Scopus
- M. H. Ulbrich and E. Y. Isacoff, “Rules of engagement for NMDA receptor subunits,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 37, pp. 14163–14168, 2008. View at Publisher · View at Google Scholar · View at Scopus
- P. Paoletti and J. Neyton, “NMDA receptor subunits: function and pharmacology,” Current Opinion in Pharmacology, vol. 7, no. 1, pp. 39–47, 2007. View at Publisher · View at Google Scholar · View at Scopus
- C.-M. Low and K. S.-L. Wee, “New insights into the not-so-new NR3 subunits of N-methyl-D-aspartate receptor: localization, structure, and function,” Molecular Pharmacology, vol. 78, no. 1, pp. 1–11, 2010. View at Publisher · View at Google Scholar · View at Scopus
- H. Furukawa and E. Gouaux, “Mechanisms of activation, inhibition and specificity: crystal structures of the NMDA receptor NR1 ligand-binding core,” EMBO Journal, vol. 22, no. 12, pp. 2873–2885, 2003. View at Publisher · View at Google Scholar · View at Scopus
- Y. Yao, C. B. Harrison, P. L. Freddolino, K. Schulten, and M. L. Mayer, “Molecular mechanism of ligand recognition by NR3 subtype glutamate receptors,” The EMBO Journal, vol. 27, no. 15, pp. 2158–2170, 2008. View at Publisher · View at Google Scholar · View at Scopus
- L. Mony, J. N. C. Kew, M. J. Gunthorpe, and P. Paoletti, “Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential,” British Journal of Pharmacology, vol. 157, no. 8, pp. 1301–1317, 2009. View at Publisher · View at Google Scholar · View at Scopus
- N. A. Anis, S. C. Berry, N. R. Burton, and D. Lodge, “The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N-methyl-aspartate,” British Journal of Pharmacology, vol. 79, no. 2, pp. 565–575, 1983. View at Publisher · View at Google Scholar · View at Scopus
- A. C. Foster and E. H. F. Wong, “The novel anticonvulsant MK-801 binds to the activated state of the N-methyl-D-aspartate receptor in rat brain,” British Journal of Pharmacology, vol. 91, no. 2, pp. 403–409, 1987. View at Publisher · View at Google Scholar · View at Scopus
- E. Karakas, N. Simorowski, and H. Furukawa, “Subunit arrangement and phenylethanolamine binding in GluN1/GluN2B NMDA receptors,” Nature, vol. 475, no. 7355, pp. 249–253, 2011. View at Publisher · View at Google Scholar · View at Scopus
- J. N. C. Kew and J. A. Kemp, “Ionotropic and metabotropic glutamate receptor structure and pharmacology,” Psychopharmacology, vol. 179, no. 1, pp. 4–29, 2005. View at Publisher · View at Google Scholar · View at Scopus
- P. Loo, A. Braunwalder, J. Lehmann, and M. Williams, “Radioligand binding to central phencyclidine recognition sites is dependent on excitatory amino acid receptor agonists,” European Journal of Pharmacology, vol. 123, no. 3, pp. 467–468, 1986. View at Publisher · View at Google Scholar · View at Scopus
- E. H. F. Wong, A. R. Knight, and G. N. Woodruff, “[3H]MK-801 labels a site on the N-methyl-D-aspartate receptor channel complex in rat brain membranes,” Journal of Neurochemistry, vol. 50, no. 1, pp. 274–281, 1988. View at Publisher · View at Google Scholar · View at Scopus
- K. Orita, S. Sasaki, M. Maeda et al., “Synthesis and evaluation of 1-{1-[5-(2′-[18F]Fluoroethyl)-2-thienyl]-cyclohexyl}piperidine as a potential in vivo radioligand for the NMDA receptor-Channel complex,” Nuclear Medicine and Biology, vol. 20, no. 7, pp. 865–873, 1993. View at Publisher · View at Google Scholar · View at Scopus
- S. Sihver, W. Sihver, Y. Andersson et al., “In vitro and in vivo characterization of (+)-3-[11C]cyano-dizocilpine,” Journal of Neural Transmission, vol. 105, no. 2-3, pp. 117–131, 1998. View at Publisher · View at Google Scholar · View at Scopus
- J. Owens, A. A. Tebbutt, A. L. McGregor et al., “Synthesis and binding characteristics of N-(1-naphthyl)-N′-(3-[125I]-iodophenyl)-N′-methylguanidine ([125I]-CNS 1261): a potential SPECT agent for imaging NMDA receptor activation,” Nuclear Medicine and Biology, vol. 27, no. 6, pp. 557–564, 2000. View at Publisher · View at Google Scholar · View at Scopus
- K. Erlandsson, R. A. Bressan, R. S. Mulligan et al., “Kinetic modelling of [123I]CNS 1261—a potential SPET tracer for the NMDA receptor,” Nuclear Medicine and Biology, vol. 30, no. 4, pp. 441–454, 2003. View at Publisher · View at Google Scholar · View at Scopus
- R. A. Bressan, K. Erlandsson, R. S. Mulligan et al., “A bolus/infusion paradigm for the novel NMDA receptor SPET tracer [123I]CNS 1261,” Nuclear Medicine and Biology, vol. 31, no. 2, pp. 155–164, 2004. View at Publisher · View at Google Scholar · View at Scopus
- J. T. Kantrowitz and D. C. Javitt, “N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?” Brain Research Bulletin, vol. 83, no. 3-4, pp. 108–121, 2010. View at Publisher · View at Google Scholar · View at Scopus
- C. H. Lin, H. Y. Lane, and G. E. Tsai, “Glutamate signaling in the pathophysiology and therapy of schizophrenia,” Pharmacology Biochemistry and Behavior, vol. 100, no. 4, pp. 665–677, 2012. View at Publisher · View at Google Scholar · View at Scopus
- L. S. Pilowsky, R. A. Bressan, J. M. Stone et al., “First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients,” Molecular Psychiatry, vol. 11, no. 2, pp. 118–119, 2006. View at Publisher · View at Google Scholar · View at Scopus
- R. A. Bressan, K. Erlandsson, J. M. Stone et al., “Impact of schizophrenia and chronic antipsychotic treatment on [123I]CNS-1261 binding to N-methyl-D-aspartate receptors in vivo,” Biological Psychiatry, vol. 58, no. 1, pp. 41–46, 2005. View at Publisher · View at Google Scholar · View at Scopus
- R. N. Waterhouse, M. Slifstein, F. Dumont et al., “In vivo evaluation of [11C]N-(2-chloro-5-thiomethylphenyl)- N′-(3-methoxy-phenyl)-N′-methylguanidine ([11C]GMOM) as a potential PET radiotracer for the PCP/NMDA receptor,” Nuclear Medicine and Biology, vol. 31, no. 7, pp. 939–948, 2004. View at Publisher · View at Google Scholar · View at Scopus
- A. Biegon, A. Gibbs, M. Alvarado, M. Ono, and S. Taylor, “In vitro and in vivo characterization of [3H]CNS-5161—a use-dependent ligand for the N-methyl-D-aspartate receptor in rat brain,” Synapse, vol. 61, no. 8, pp. 577–586, 2007. View at Publisher · View at Google Scholar · View at Scopus
- M. C. Asselin, A. Hammers, D. Turton, S. Osman, M. Koepp, and D. Brooks, “Initial kinetic analysis of the in vivo binding of the putative NMDA receptor ligand [11C]CNS 5161 in humans,” Neuroimage, vol. 22, p. T137, 2004. View at Google Scholar
- E. G. Robins, Y. Zhao, I. Khan, A. Wilson, S. K. Luthra, and E. Årstad, “Synthesis and in vitro evaluation of 18F-labelled S-fluoroalkyl diarylguanidines: novel high-affinity NMDA receptor antagonists for imaging with PET,” Bioorganic and Medicinal Chemistry Letters, vol. 20, no. 5, pp. 1749–1751, 2010. View at Publisher · View at Google Scholar · View at Scopus
- C. J. McGinnity, A. Hammers, D. A. R. Barros et al., “Initial evaluation of 18F-GE-179, a putative PEt tracer for activated N-methyl D-aspartate receptors,” Journal of Nuclear Medicine, vol. 55, no. 3, pp. 423–430, 2014. View at Publisher · View at Google Scholar · View at Scopus
- W. Danysz and C. G. Parsons, “Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications,” Pharmacological Reviews, vol. 50, no. 4, pp. 597–664, 1998. View at Google Scholar · View at Scopus
- R. N. Waterhouse, A. Sultana, and M. Laruelle, “In vivo evaluation of [11C]-3-[2-[(3-methoxyphenylamino)carbonyl]ethenyl]-4,6- dichloroindole-2-carboxylic acid ([11C]3MPICA) as a PET radiotracer for the glycine site of the NMDA ion channel,” Nuclear Medicine and Biology, vol. 29, no. 8, pp. 791–794, 2002. View at Publisher · View at Google Scholar · View at Scopus
- M. Piel, R. Schirrmacher, S. Höhnemann et al., “Synthesis and evaluation of 5, 7-dichloro-4-(3- 4-[4-(2-[18F]fluoroethyl)-piperazin-1-yl]-phenyl-ureido)-1, 2, 3, 4-tetrahydroquinoline-2-carboxylic acid as a potential NMDA ligand to study glutamatergic neurotransmission in vivo,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 46, pp. 645–659, 2003. View at Google Scholar
- J. J. Kulagowski, R. Baker, N. R. Curtis et al., “3′-(Arylmethyl)- and 3′-(aryloxy)-3-phenyl-4-hydroxyquinolin-2(1H)-ones: orally active antagonists of the glycine site on the NMDA receptor,” Journal of Medicinal Chemistry, vol. 37, no. 10, pp. 1402–1405, 1994. View at Publisher · View at Google Scholar · View at Scopus
- M. Rowley, J. J. Kulagowski, A. P. Watt et al., “Effect of plasma protein binding-on in vivo activity and brain penetration of glycine/NMDA receptor antagonists,” Journal of Medicinal Chemistry, vol. 40, no. 25, pp. 4053–4068, 1997. View at Publisher · View at Google Scholar · View at Scopus
- T. Haradahira, M.-R. Zhang, J. Maeda et al., “A strategy for increasing the brain uptake of a radioligand in animals: use of a drug that inhibits plasma protein binding,” Nuclear Medicine and Biology, vol. 27, no. 4, pp. 357–360, 2000. View at Publisher · View at Google Scholar · View at Scopus
- T. Haradahira, M.-R. Zhang, J. Maeda et al., “A prodrug of NMDA/Glycine site antagonist, L-703,717, with improved BBB permeability: 4-acetoxy derivative and its positron-emitter labeled analog,” Chemical and Pharmaceutical Bulletin, vol. 49, no. 2, pp. 147–150, 2001. View at Publisher · View at Google Scholar · View at Scopus
- R. Matsumoto, T. Haradahira, H. Ito et al., “Measurement of glycine binding site of N-methyl-D-asparate receptors in living human brain using 4-acetoxy derivative of L-703,717, 4-acetoxy-7-chloro- 3-[3-(4-[11C] methoxybenzyl) phenyl]-2(1H)-quinolone (AcL703) with positron emission tomography,” Synapse, vol. 61, no. 10, pp. 795–800, 2007. View at Publisher · View at Google Scholar · View at Scopus
- T. Fuchigami, T. Haradahira, N. Fujimoto et al., “Difference in brain distributions of carbon 11-labeled 4-hydroxy-2(1H)-quinolones as PET radioligands for the glycine-binding site of the NMDA ion channel,” Nuclear Medicine and Biology, vol. 35, no. 2, pp. 203–212, 2008. View at Publisher · View at Google Scholar · View at Scopus
- T. Fuchigami, T. Haradahira, N. Fujimoto et al., “Development of N-[11C]methylamino 4-hydroxy-2(1H)-quinolone derivatives as PET radioligands for the glycine-binding site of NMDA receptors,” Bioorganic and Medicinal Chemistry, vol. 17, no. 15, pp. 5665–5675, 2009. View at Publisher · View at Google Scholar · View at Scopus
- A. Hashimoto, T. Nishikawa, T. Oka, and K. Takahashi, “Endogenous D-serine in rat brain: N-methyl-D-aspartate receptor-related distribution and aging,” Journal of Neurochemistry, vol. 60, no. 2, pp. 783–786, 1993. View at Publisher · View at Google Scholar · View at Scopus
- M. J. Schell, R. O. Brady Jr., M. E. Molliver, and S. H. Snyder, “D-serine as a neuromodulator: regional and developmental localizations in rat brain glia resemble NMDA receptors,” Journal of Neuroscience, vol. 17, no. 5, pp. 1604–1615, 1997. View at Google Scholar · View at Scopus
- M. J. Schell, M. E. Molliver, and S. H. Snyder, “D-serine, an endogenous synaptic modulator: localization to astrocytes and glutamate-stimulated release,” Proceedings of the National Academy of Sciences of the United States of America, vol. 92, no. 9, pp. 3948–3952, 1995. View at Publisher · View at Google Scholar · View at Scopus
- T. Haradahira, T. Okauchi, J. Maeda et al., “Effects of endogenous agonists, glycine and D-serine, on in vivo specific binding of [11C]L-703,717, a PET radioligand for the glycine-binding site of NMDA receptors,” Synapse, vol. 50, no. 2, pp. 130–136, 2003. View at Publisher · View at Google Scholar · View at Scopus
- K. R. Gogas, “Glutamate-based therapeutic approaches: NR2B receptor antagonists,” Current Opinion in Pharmacology, vol. 6, no. 1, pp. 68–74, 2006. View at Publisher · View at Google Scholar · View at Scopus
- P. Malherbe, V. Mutel, C. Broger et al., “Identification of critical residues in the amino terminal domain of the human NR2B subunit involved in the RO 25-6981 binding pocket,” Journal of Pharmacology and Experimental Therapeutics, vol. 307, no. 3, pp. 897–905, 2003. View at Publisher · View at Google Scholar · View at Scopus
- F. Menniti, B. Chenard, M. Collins, M. Ducat, I. Shalaby, and F. White, “CP-101,606, a potent neuroprotectant selective for forebrain neurons,” European Journal of Pharmacology, vol. 331, no. 2-3, pp. 117–126, 1997. View at Publisher · View at Google Scholar · View at Scopus
- T. Haradahira, J. Maeda, T. Okauchi et al., “Synthesis, in vitro and in vivo pharmacology of a C-11 labeled analog of CP-101,606, (±)threo-1-(4-hydroxyphenyl)-2-[4-hydroxy-4- (p-[11C]methoxyphenyl)piperidino]-1-propanol, as a PET tracer for NR2B subunit-containing NMDA receptors,” Nuclear Medicine and Biology, vol. 29, no. 5, pp. 517–525, 2002. View at Publisher · View at Google Scholar · View at Scopus
- H. Mori and M. Mishina, “Structure and function of the NMDA receptor channel,” Neuropharmacology, vol. 34, no. 10, pp. 1219–1237, 1995. View at Publisher · View at Google Scholar · View at Scopus
- G. Roger, B. Lagnel, L. Besret et al., “Synthesis, radiosynthesis and in vivo evaluation of 5-[3-(4- benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzoimidazol-2-[ 11C]one, as a potent NR1A/2B subtype selective NMDA PET radiotracer,” Bioorganic and Medicinal Chemistry, vol. 11, no. 24, pp. 5401–5408, 2003. View at Publisher · View at Google Scholar · View at Scopus
- G. Roger, F. Dollé, B. de Bruin et al., “Radiosynthesis and pharmacological evaluation of [11C]EMD-95885: a high affinity ligand for NR2B-containing NMDA receptors,” Bioorganic and Medicinal Chemistry, vol. 12, no. 12, pp. 3229–3237, 2004. View at Publisher · View at Google Scholar · View at Scopus
- T. Fuchigami, H. Yamaguchi, M. Ogawa et al., “Synthesis and biological evaluation of radio-iodinated benzimidazoles as SPECT imaging agents for NR2B subtype of NMDA receptor,” Bioorganic and Medicinal Chemistry, vol. 18, no. 21, pp. 7497–7506, 2010. View at Publisher · View at Google Scholar · View at Scopus
- F. Dollé, H. Valette, S. Demphel et al., “Radiosynthesis and in vivo evaluation of [11C]Ro-647312: A novel NR1/2B subtype selective NMDA receptor radioligand,” Journal of Labelled Compounds and Radiopharmaceuticals, vol. 47, no. 13, pp. 911–920, 2004. View at Publisher · View at Google Scholar · View at Scopus
- E. Årstad, S. Platzer, A. Berthele et al., “Towards NR2B receptor selective imaging agents for PET-synthesis and evaluation of N-[11C]-(2-methoxy)benzyl (E)-styrene-, 2-naphthyl- and 4-trifluoromethoxyphenylamidine,” Bioorganic and Medicinal Chemistry, vol. 14, no. 18, pp. 6307–6313, 2006. View at Publisher · View at Google Scholar · View at Scopus
- C. Addy, C. Assaid, D. Hreniuk et al., “Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease,” Journal of Clinical Pharmacology, vol. 49, no. 7, pp. 856–864, 2009. View at Publisher · View at Google Scholar · View at Scopus
- R. Koudih, G. Gilbert, M. Dhilly et al., “Synthesis and in vitro characterization of trans- and cis-[18F]-4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]-3- fluoropiperidine-1-carboxylates as new potential PET radiotracer candidates for the NR2B subtype N-methyl-d-aspartate receptor,” European Journal of Medicinal Chemistry, vol. 53, pp. 408–415, 2012. View at Publisher · View at Google Scholar · View at Scopus
- N. Pitsikas, “The metabotropic glutamate receptors: potential drug targets for the treatment of anxiety disorders?” European Journal of Pharmacology, vol. 723, no. 1, pp. 181–184, 2014. View at Publisher · View at Google Scholar · View at Scopus
- S. Chaki, Y. Ago, A. Palucha-Paniewiera, F. Matrisciano, and A. Pilc, “MGlu2/3 and mGlu5 receptors: potential targets for novel antidepressants,” Neuropharmacology, vol. 66, pp. 40–52, 2013. View at Publisher · View at Google Scholar · View at Scopus
- H.-G. Lee, X. Zhu, M. J. O'Neill et al., “The role of metabotropic glutamate receptors in Alzheimer's disease,” Acta Neurobiologiae Experimentalis, vol. 64, no. 1, pp. 89–98, 2004. View at Google Scholar · View at Scopus
- P. N. Vinson and P. J. Conn, “Metabotropic glutamate receptors as therapeutic targets for schizophrenia,” Neuropharmacology, vol. 62, no. 3, pp. 1461–1472, 2012. View at Publisher · View at Google Scholar · View at Scopus
- F. Gasparini, T. Di Paolo, and B. Gomez-Mancilla, “Metabotropic glutamate receptors for parkinson's disease therapy,” Parkinson's Disease, vol. 2013, Article ID 196028, 11 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
- R. T. Ngomba, I. Santolini, T. E. Salt et al., “Metabotropic glutamate receptors in the thalamocortical network: Strategic targets for the treatment of absence epilepsy,” Epilepsia, vol. 52, no. 7, pp. 1211–1222, 2011. View at Publisher · View at Google Scholar · View at Scopus
- F. Nicoletti, J. Bockaert, G. L. Collingridge et al., “Metabotropic glutamate receptors: from the workbench to the bedside,” Neuropharmacology, vol. 60, no. 7-8, pp. 1017–1041, 2011. View at Publisher · View at Google Scholar · View at Scopus
- F. Ferraguti and R. Shigemoto, “Metabotropic glutamate receptors,” Cell and Tissue Research, vol. 326, no. 2, pp. 483–504, 2006. View at Publisher · View at Google Scholar · View at Scopus
- A. Slassi, M. Isaac, L. Edwards et al., “Recent advances in non-competitive mGlu5 receptor antogonists and their potential therapeutic applications,” Current Topics in Medicinal Chemistry, vol. 5, no. 9, pp. 897–911, 2005. View at Publisher · View at Google Scholar · View at Scopus
- P. J. Conn, C. W. Lindsley, and C. K. Jones, “Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia,” Trends in Pharmacological Sciences, vol. 30, no. 1, pp. 25–31, 2009. View at Publisher · View at Google Scholar · View at Scopus
- Y. Huang, R. Narendran, F. Bischoff et al., “A positron emission tomography radioligand for the in vivo labeling of metabotropic glutamate 1 receptor: (3-Ethyl-2-[11C]methyl-6- quinolinyl)(cis-4-methoxycyclohexyl)methanone,” Journal of Medicinal Chemistry, vol. 48, no. 16, pp. 5096–5099, 2005. View at Publisher · View at Google Scholar · View at Scopus
- Y. Huang, R. Narendran, F. Bischoff et al., “Synthesis and characterization of two pet radioligands for the metabotropic glutamate 1 (mGlu1) receptor,” Synapse, vol. 66, no. 12, pp. 1002–1014, 2012. View at Publisher · View at Google Scholar · View at Scopus
- K. Yanamoto, F. Konno, C. Odawara et al., “Radiosynthesis and evaluation of [11C]YM-202074 as a PET ligand for imaging the metabotropic glutamate receptor type 1,” Nuclear Medicine and Biology, vol. 37, no. 5, pp. 615–624, 2010. View at Publisher · View at Google Scholar · View at Scopus
- E. D. Hostetler, W. Eng, A. D. Joshi et al., “Synthesis, characterization, and monkey PET studies of [18F]MK-1312, a PET tracer for quantification of mGluR1 receptor occupancy by MK-5435,” Synapse, vol. 65, no. 2, pp. 125–135, 2011. View at Publisher · View at Google Scholar · View at Scopus
- M. Fujinaga, J. Maeda, J. Yui et al., “Characterization of 1-(2-[18F]fluoro-3-pyridyl)-4-(2-isopropyl- 1-oxo- isoindoline-5-yl)-5-methyl-1H-1,2,3-triazole, a PET ligand for imaging the metabotropic glutamate receptor type 1 in rat and monkey brains,” Journal of Neurochemistry, vol. 121, no. 1, pp. 115–124, 2012. View at Publisher · View at Google Scholar · View at Scopus
- A. Satoh, Y. Nagatomi, Y. Hirata et al., “Discovery and in vitro and in vivo profiles of 4-fluoro-N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide as novel class of an orally active metabotropic glutamate receptor 1 (mGluR1) antagonist,” Bioorganic and Medicinal Chemistry Letters, vol. 19, no. 18, pp. 5464–5468, 2009. View at Publisher · View at Google Scholar · View at Scopus
- T. Yamasaki, M. Fujinaga, Y. Yoshida et al., “Radiosynthesis and preliminary evaluation of 4-[18F]fluoro-N-[4- [6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methylbenzamide as a new positron emission tomography ligand for metabotropic glutamate receptor subtype 1,” Bioorganic and Medicinal Chemistry Letters, vol. 21, no. 10, pp. 2998–3001, 2011. View at Publisher · View at Google Scholar · View at Scopus
- T. Yamasaki, M. Fujinaga, J. Maeda et al., “Imaging for metabotropic glutamate receptor subtype 1 in rat and monkey brains using PET with [18F]FITM,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 4, pp. 632–641, 2012. View at Publisher · View at Google Scholar · View at Scopus
- T. Yamasaki, M. Fujinaga, K. Kawamura et al., “In vivo measurement of the affinity and density of metabotropic glutamate receptor subtype 1 in rat brain using 18F-FITM in small-animal PET,” Journal of Nuclear Medicine, vol. 53, no. 10, pp. 1601–1607, 2012. View at Publisher · View at Google Scholar · View at Scopus
- M. Fujinaga, T. Yamasaki, J. Yui et al., “Synthesis and evaluation of novel radioligands for positron emission tomography imaging of metabotropic glutamate receptor subtype 1 (mGluR1) in rodent brain,” Journal of Medicinal Chemistry, vol. 55, no. 5, pp. 2342–2352, 2012. View at Publisher · View at Google Scholar · View at Scopus
- J. Yui, L. Xie, M. Fujinaga et al., “Monitoring neuroprotective effects using positron emission tomography with [11C]ITMM, a radiotracer for metabotropic glutamate 1 receptor,” Stroke, vol. 44, no. 9, pp. 2567–2572, 2013. View at Publisher · View at Google Scholar · View at Scopus
- J. Toyohara, M. Sakata, K. Oda et al., “Initial human PET studies of metabotropic glutamate receptor type 1 ligand 11C-ITMM,” Journal of Nuclear Medicine, vol. 54, no. 8, pp. 1302–1307, 2013. View at Publisher · View at Google Scholar · View at Scopus
- M. Fujinaga, T. Yamasaki, J. Maeda et al., “Development of N-[4-[6-(isopropylamino)pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methyl-4-[11C]methylbenzamide for positron emission tomography imaging of metabotropic glutamate 1 receptor in monkey brain,” Journal of Medicinal Chemistry, vol. 55, no. 24, pp. 11042–11051, 2012. View at Publisher · View at Google Scholar · View at Scopus
- T. Yamasaki, J. Maeda, M. Fujinaga et al., “PET brain kinetics studies of 11C-ITMM and 11C-ITDM, radioprobes for metabotropic glutamate receptor type 1, in a nonhuman primate,” The American Journal of Nuclear Medicine and Molecular Imaging, vol. 4, pp. 260–269, 2014. View at Google Scholar
- T. Yamasaki, M. Fujinaga, J. Yui et al., “Noninvasive quantification of metabotropic glutamate receptor type 1 with [11C]ITDM: a small-animal PET study,” Journal of Cerebral Blood Flow and Metabolism, vol. 34, no. 4, pp. 606–612, 2014. View at Publisher · View at Google Scholar · View at Scopus
- R. Xu, P. Zanotti-Fregonara, S. S. Zoghbi et al., “Synthesis and evaluation in monkey of [18F]4-Fluoro- N-methyl-N-(4-(6-(methylamino)pyrimidin-4-yl)thiazol-2-yl)benzamide ([ 18F]FIMX): a promising radioligand for PET imaging of brain metabotropic glutamate receptor 1 (mGluR1),” Journal of Medicinal Chemistry, vol. 56, no. 22, pp. 9146–9155, 2013. View at Publisher · View at Google Scholar · View at Scopus
- P. Zanotti-Fregonara, S. Zoghbi, J. S. Liow et al., “[18F]FIMX is a promising tracer to quantify metabotropic glutamate receptor 1 (mGluR1) in human brain,” Journal of Nuclear Medicine, vol. 55, supplement 1, p. 359, 2014. View at Google Scholar
- T. G. Hamill, S. Krause, C. Ryan et al., “Synthesis, characterization, and first successful monkey imaging studies of metabotropic glutamate receptor subtype 5 (mGluR5) PET radiotracers,” Synapse, vol. 56, no. 4, pp. 205–216, 2005. View at Publisher · View at Google Scholar · View at Scopus
- J.-Q. Wang, W. Tueckmantel, A. Zhu, D. Pellegrino, and A.-L. Brownell, “Synthesis and preliminary biological evaluation of 3-[18F] fluoro-5-(2-pyridinylethynyl)benzonitrile as a PET radiotracer for imaging metabotropic glutamate receptor subtype 5,” Synapse, vol. 61, no. 12, pp. 951–961, 2007. View at Publisher · View at Google Scholar · View at Scopus
- D. F. Wong, R. Waterhouse, H. Kuwabara et al., “18F-FPEB, a PET radiopharmaceutical for quantifying metabotropic glutamate 5 receptors: a first-in-human study of radiochemical safety, biokinetics, and radiation dosimetry,” Journal of Nuclear Medicine, vol. 54, no. 3, pp. 388–396, 2013. View at Publisher · View at Google Scholar · View at Scopus
- S. M. Ametamey, L. J. Kessler, M. Honer et al., “Radiosynthesis and preclinical evaluation of 11C-ABP688 as a probe for imaging the metabotropic glutamate receptor subtype 5,” Journal of Nuclear Medicine, vol. 47, no. 4, pp. 698–705, 2006. View at Google Scholar · View at Scopus
- S. M. Ametamey, V. Treyer, J. Streffer et al., “Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688,” Journal of Nuclear Medicine, vol. 48, no. 2, pp. 247–252, 2007. View at Google Scholar · View at Scopus
- M. Kågedal, Z. Cselényi, S. Nyberg et al., “A positron emission tomography study in healthy volunteers to estimate mGluR5 receptor occupancy of AZD2066—estimating occupancy in the absence of a reference region,” NeuroImage, vol. 82, pp. 160–169, 2013. View at Publisher · View at Google Scholar · View at Scopus
- K. Kawamura, T. Yamasaki, K. Kumata et al., “Binding potential of (E)-[11C]ABP688 to metabotropic glutamate receptor subtype 5 is decreased by the inclusion of its 11C-labelled Z-isomer,” Nuclear Medicine and Biology, vol. 41, no. 1, pp. 17–23, 2014. View at Publisher · View at Google Scholar · View at Scopus
- F. G. Siméon, A. K. Brown, S. S. Zoghbi, V. M. Patterson, R. B. Innis, and V. W. Pike, “Synthesis and simple 18F-labeling of 3-fluoro-5-(2-(2- (fluoromethyl)thiazol-4-yl)ethynyl)benzonitrile as a high affinity radioligand for imaging monkey brain metabotropic glutamate subtype-5 receptors with positron emission tomography,” Journal of Medicinal Chemistry, vol. 50, no. 14, pp. 3256–3266, 2007. View at Publisher · View at Google Scholar · View at Scopus
- H. U. Shetty, S. S. Zoghbi, F. G. Simeon et al., “Radiodefluorination of 3-fluoro-5-(2-(2-[18F](fluoromethyl)-thiazol-4-yl)ethynyl)benzonitrile ([18F]SP203, a radioligand for imaging brain metabotropic glutamate subtype-5 receptors with positron emission tomography, occurs by glutathionylation in rat brain,” Journal of Pharmacology and Experimental Therapeutics, vol. 327, pp. 727–735, 2008. View at Google Scholar
- J. J. P. Bogaards, J. C. Venekamp, F. G. C. Salmon, and P. J. Van Bladeren, “Conjugation of isoprene monoepoxides with glutathione, catalyzed by α, μ, π and θ-class glutathione S-transferases of rat and man,” Chemico-Biological Interactions, vol. 117, no. 1, pp. 1–14, 1999. View at Publisher · View at Google Scholar · View at Scopus
- A. K. Brown, Y. Kimura, S. S. Zoghbi et al., “Metabotropic glutamate subtype 5 receptors are quantified in the human brain with a novel radioligand for PET,” Journal of Nuclear Medicine, vol. 49, no. 12, pp. 2042–2048, 2008. View at Publisher · View at Google Scholar · View at Scopus
- Y. Hao, R. Martin-Fardon, and F. Weiss, “Behavioral and functional evidence of metabotropic glutamate receptor 2/3 and metabotropic glutamate receptor 5 dysregulation in cocaine-escalated rats: factor in the transition to dependence,” Biological Psychiatry, vol. 68, no. 3, pp. 240–248, 2010. View at Publisher · View at Google Scholar · View at Scopus
- D. Martinez, M. Slifstein, N. Nabulsi et al., “Imaging glutamate homeostasis in cocaine addiction with the metabotropic glutamate receptor 5 positron emission tomography radiotracer [11C]ABP688 and magnetic resonance spectroscopy,” Biological Psychiatry, vol. 75, no. 2, pp. 165–171, 2014. View at Publisher · View at Google Scholar · View at Scopus
- M. S. Milella, L. Marengo, K. Larcher et al., “Limbic system mGluR5 availability in cocaine dependent subjects: a high-resolution PET [11C]ABP688 study,” Neuroimage, vol. 98, pp. 195–202, 2014. View at Google Scholar
- N. E. Paterson and A. Markou, “The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats,” Psychopharmacology, vol. 179, no. 1, pp. 255–261, 2005. View at Publisher · View at Google Scholar · View at Scopus
- M. I. Palmatier, X. Liu, E. C. Donny, A. R. Caggiula, and A. F. Sved, “Metabotropic glutamate 5 receptor (mGluR5) antagonists decrease nicotine seeking, but do not affect the reinforcement enhancing effects of nicotine,” Neuropsychopharmacology, vol. 33, no. 9, pp. 2139–2147, 2008. View at Publisher · View at Google Scholar · View at Scopus
- F. Akkus, S. M. Ametamey, V. Treyer et al., “Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 2, pp. 737–742, 2013. View at Publisher · View at Google Scholar · View at Scopus
- L. R. Merlin, “Differential roles for mGluR1 and mGluR5 in the persistent prolongation of epileptiform bursts,” Journal of Neurophysiology, vol. 87, no. 1, pp. 621–625, 2002. View at Google Scholar · View at Scopus
- T. Kirschstein, M. Bauer, L. Müller et al., “Loss of metabotropic glutamate receptor-dependent long-term depression via downregulation of mGluR5 after status epilepticus,” The Journal of Neuroscience, vol. 27, no. 29, pp. 7696–7704, 2007. View at Publisher · View at Google Scholar · View at Scopus
- H. Choi, Y. K. Kim, S. W. Oh et al., “In vivo imaging of mGluR5 changes during epileptogenesis using [11C]ABP688 PET in pilocarpine-induced epilepsy rat model,” PLoS ONE, vol. 9, no. 3, Article ID e92765, 2014. View at Publisher · View at Google Scholar · View at Scopus
- A. Deschwanden, B. Karolewicz, A. M. Feyissa et al., “Reduced metabotropic glutamate receptor 5 density in major depression determined by [11C]ABP688 PET and postmortem study,” The American Journal of Psychiatry, vol. 168, no. 7, pp. 727–734, 2011. View at Publisher · View at Google Scholar · View at Scopus
- M. J. Fell, D. L. McKinzie, J. A. Monn, and K. A. Svensson, “Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia,” Neuropharmacology, vol. 62, no. 3, pp. 1473–1483, 2012. View at Publisher · View at Google Scholar · View at Scopus
- M. Amalric, S. Lopez, C. Goudet et al., “Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's disease,” Neuropharmacology, vol. 66, pp. 53–64, 2013. View at Publisher · View at Google Scholar · View at Scopus
- N. K. Parelkar and J. Q. Wang, “Upregulation of metabotropic glutamate receptor 8 mRNA expression in the rat forebrain after repeated amphetamine administration,” Neuroscience Letters, vol. 433, no. 3, pp. 250–254, 2008. View at Publisher · View at Google Scholar · View at Scopus
- J. I. Andrés, J. Alcázar, J. M. Cid et al., “Synthesis, evaluation, and radiolabeling of new potent positive allosteric modulators of the metabotropic glutamate receptor 2 as potential tracers for positron emission tomography imaging,” Journal of Medicinal Chemistry, vol. 55, no. 20, pp. 8685–8699, 2012. View at Publisher · View at Google Scholar · View at Scopus
- K. V. Laere, M. Koole, J. Hoon et al., “Biodistribution, dosimetry and kinetic modeling of [11C]JNJ-42491293, a PET tracer for the mGluR2 receptor in the human brain,” Journal of Nuclear Medicine, vol. 53, supplement 1, article 355, 2012. View at Google Scholar
- D. W. Engers, C. M. Niswender, C. D. Weaver et al., “Synthesis and evaluation of a series of heterobiarylamides that are centrally penetrant metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulators (PAMs),” Journal of Medicinal Chemistry, vol. 52, no. 14, pp. 4115–4118, 2009. View at Publisher · View at Google Scholar · View at Scopus
- K.-E. Kil, Z. Zhang, K. Jokivarsi et al., “Radiosynthesis of N-(4-chloro-3-[11C]methoxyphenyl)-2- picolinamide ([11C]ML128) as a PET radiotracer for metabotropic glutamate receptor subtype 4 (mGlu4),” Bioorganic and Medicinal Chemistry, vol. 21, no. 19, pp. 5955–5962, 2013. View at Publisher · View at Google Scholar · View at Scopus
- M. Nakamura, H. Kurihara, G. Suzuki, M. Mitsuya, M. Ohkubo, and H. Ohta, “Isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 antagonists,” Bioorganic and Medicinal Chemistry Letters, vol. 20, no. 2, pp. 726–729, 2010. View at Publisher · View at Google Scholar · View at Scopus
- M. L. Vallano, B. Lambolez, E. Audinat, and J. Rossier, “Neuronal activity differentially regulates NMDA receptor subunit expression in cerebellar granule cells,” Journal of Neuroscience, vol. 16, no. 2, pp. 631–639, 1996. View at Google Scholar · View at Scopus
- K. W. Roche, S. Standley, J. McCallum, C. Dune Ly, M. D. Ehlers, and R. J. Wenthold, “Molecular determinants of NMDA receptor internalization,” Nature Neuroscience, vol. 4, no. 8, pp. 794–802, 2001. View at Publisher · View at Google Scholar · View at Scopus
- T. Hayashi, G. M. Thomas, and R. L. Huganir, “Dual palmitoylation of NR2 subunits regulates NMDA receptor trafficking,” Neuron, vol. 64, no. 2, pp. 213–226, 2009. View at Publisher · View at Google Scholar · View at Scopus